Pfizer reported that Lyrica benefited patients with Restless Legs Syndrome in a late-stage clinical study of more than 700 patients. Lyrica, which is one of Pfizer’s top-selling products, is approved to treat diabetic nerve pain, pain after shingles, and fibromyalgia, among other conditions. Pfizer said it does not have plans at this time to seek regulatory approval for Lyrica to address Restless Legs Syndrome.
